ClinicalTrials.gg
RecruitingNCT07250087Updated Mar 27, 2026

Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL

A Phase 1 interventional study of Asciminib in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, sponsored by H. Lee Moffitt Cancer Center and Research Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by H. Lee Moffitt Cancer Center and Research Institute · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Philadelphia Chromosome with a site in United States — 4 open to participants now, 7 under way, 4 of them phase 3. Philadelphia Chromosome · United States.

Planned enrollment
12th of 19
36 · median 130
Started
2026
with 1 other
Phase 1
5 of 19
2 open now
Registered
18th of 19
by date
Lead sponsor
1 of 19
H. Lee Moffitt Cancer Center and Research Institute

Among the 19 studies in Philadelphia Chromosome with a site in United States, this one is the 12th largest by planned enrollment, is one of 2 that started in 2026, is one of 5 in phase 1, and was the 18th registered.

Philadelphia Chromosome

52 studies on the registry are indexed under Philadelphia Chromosome; 13 are open to participants now.

Browse Philadelphia Chromosome studies →

Open to participants now

4 of the 19 studies in Philadelphia Chromosome with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Philadelphia Chromosome studies recruiting now, 5 (50%) set no upper age limit and 5 (50%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Philadelphia Chromosome with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to see if a study drug called asciminib is safe and okay for people to take after they've had treatment for a type of blood cancer called Philadelphia Chromosome

Positive Acute Lymphoblastic Leukemia (Ph+ B-ALL). We're looking at two groups of adults:

one group had an Allogeneic Stem Cell Transplant (alloHCT) cohort A, and the other group had chimeric antigen receptor T cell (CAR T) therapy, cohort B. We also want to figure out what the best dose of asciminib is to use moving forward in future studies.

03

Conditions studied

  • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Diagnosis of Ph+ B-ALL with detectable Philadelphia chromosome abnormalities
  • Morphologic remission (\<5% marrow blasts)
  • performance status 0-2
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Active disease (>5% blasts)
  • Grade II-IV acute requiring systemic
  • Significant organ dysfunction or uncontrolled infection
  • Pregnancy or breastfeeding
  • Prior CAR T product
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Patients post-alloHCT

    Individuals who have previously undergone an allogeneic stem cell transplant (alloHCT).

    Drug: Asciminib

  • Experimental
    Patients post-CAR T cell therapy

    Individuals who have received chimeric antigen receptor T cell therapy (CAR T).

    Drug: Asciminib

Interventions

  • Treatment will be administered on an outpatient basis.

06

What researchers measure

Primary outcomes

  1. Recommended Phase 2 Dose

    The MTD is defined as the highest dose level at which one or none of six patients experience a DLT.

    Time frame: Up to 24 months

Secondary outcomes

  1. Relapse-free survival (RFS)

    Relapse-free survival (RFS) is defined as the time from starting asciminib to the date of relapse or death, whichever comes first.

    Time frame: Up to 24 Months

  2. Overall survival (OS)

    Overall survival (OS) is defined as the time from starting asciminib to the date of death.

    Time frame: Up to 24 Months

07

Study locations

1 of 1 sites recruiting
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Recruiting
    • Rawan Faramand, MD · Principal investigator
    • Melissa Alsina, MD · Sub investigator
    • Nelli Bejanyan, MD · Sub investigator
    • Omar Castaneda Puglianini, MD · Sub investigator
    • Ciara Freeman, MD · Sub investigator
    • Doris Hansen, MD · Sub investigator
    • Michael Jain, MD · Sub investigator
    • Farhad Khimani, MD · Sub investigator
    • Aleksandr Lazaryan, MD · Sub investigator
    • Hien Liu, MD · Sub investigator
    • Frederick Locke, MD · Sub investigator
    • Asmita Mishra, MD · Sub investigator
    • Taiga Nishihori, MD · Sub investigator
    • Lia Perez, MD · Sub investigator
    • Sayeef Mirza, MD · Sub investigator
    • Fabiana Perna, MD · Sub investigator
    • Joseph Pidala, MD · Sub investigator
    • Reshma Ramlal, MD · Sub investigator
    • Nancy Torres Luna, MD · Sub investigator
    • Bijal Shah, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Nov 2029, 46 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 26, 2025
StartActual
Jan 21, 2026
Primary completionEst.
Nov 2029
CompletionEst.
Nov 2029
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07250087
Collaborators
Novartis
Responsible party
Sponsor
First posted
Nov 26, 2025
Start date
Jan 21, 2026
Primary completion
Nov 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Mar 27, 2026

Study contacts

Valerie Trujillo
Contact
Valerie.Trujillo@moffitt.org
813-745-3178
Rawan Faramand, MD
principal investigator · Moffitt Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asciminib

Start the discussion